《Nature,4月20日,The need for urogenital tract monitoring in COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-21
  • The need for urogenital tract monitoring in COVID-19

    Shangqian Wang, Xiang Zhou, Tongtong Zhang & Zengjun Wang

    Nature Reviews Urology (2020)

    Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which invades a cell through binding to the ACE2 receptor and TMPRSS2 priming. Patients with severe disease predominantly present with pneumonia-related symptoms. However, evidence suggests that COVID-19 infection also has implications for the urogenital tract. Thus, urogenital organs should be considered when treating COVID-19.

  • 原文来源:https://www.nature.com/articles/s41585-020-0319-7
相关报告
  • 《Nature,4月21日,The potential danger of suboptimal antibody responses in COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-22
    • The potential danger of suboptimal antibody responses in COVID-19 Akiko Iwasaki & Yexin Yang Nature Reviews Immunology (2020) There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.
  • 《Nature,4月3日,Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-04
    • Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic Andrew M. South, Laurie Tomlinson, Daniel Edmonston, Swapnil Hiremath & Matthew A. Sparks Nature Reviews Nephrology (2020) The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.